IDEAYA Biosciences and Hengrui Pharmaceuticals Announce Oral Presentation at IASLC 2025 World Conference on Lung Cancer for IDE849 (SHR-4849), a Potential First-in-Class DLL3-TOP1 ADC

About this update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A

[{"type":"list","items":[{"val":[{"type":"text","content":"Clinical efficacy and safety data will be presented from over 70 small-cell lung cancer (SCLC) patients in Hengrui's ongoing, multi-site, open label Phase 1 trial","length":166,"tagName":"p"}]},{"val":[{"type":"text","content":"Data will include patients from the dose escalation and at multiple expansion doses","length":83,"tagName":"p"}]},{"val":[{"type":"text","content":"U.S. Phase 1 trial of IDE849 in SCLC patients initiated in 3Q 2025","length":66,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":315,"olType":false},{"type":"text","content":"JIANGSU, China and SOUTH SAN FRANCISCO, Calif., July 22, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a leading precision medicine oncology company, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui), a global pharmaceutical company focused on scientific and technological innovation, today announced the publication of an abstract for an oral presentation on IDE849 (SHR-4849) at the IASLC 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (WCLC), taking place September 6-9, 2025 in Barcelona, Spain. The presentation will cover efficacy and safety results in SCLC from the Phase 1 trial Hengrui is conducting in China for IDE849 (SHR-4849), a potential first-in-class delta-like ligand 3 (DLL3)-targeting Topoisomerase-1 (TOP1) payload antibody drug conjugate (ADC). DLL3 is upregulated across multiple solid tumor types where significant unmet need remains, including SCLC, neuroendocrine tumors (NETs), non-small cell lung cancer (NSCLC) and melanoma.","length":1044,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/IDEAYA Biosciences, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":263,"url":"https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7kIIgx9lBKLOOeuEoOJXpA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ2NDtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/74efd2e2f7cc28d3a6ce5efb40fb6e7d","width":400,"height":263}},"href":"https://mma.prnewswire.com/media/820568/IDEAYA_Logo.html","hrefExternal":true,"rel":"nofollow"},{"type":"text","content":"IDEAYA will also ha...

More updates from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class A